• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

黄酮醋酸在晚期恶性黑色素瘤和结直肠癌中的II期试验。

Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.

作者信息

Kerr D J, Maughan T, Newlands E, Rustin G, Bleehen N M, Lewis C, Kaye S B

机构信息

CRC Department of Medical Oncology, University of Glasgow, UK.

出版信息

Br J Cancer. 1989 Jul;60(1):104-6. doi: 10.1038/bjc.1989.230.

DOI:10.1038/bjc.1989.230
PMID:2803908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2247346/
Abstract

Flavone acetic acid (FAA), 8.6 gm-2 has been administered by 6h intravenous infusion to 19 patients with advanced colorectal carcinoma and 15 patients with advanced malignant melanoma. The drug associated toxicity was generally mild and as predicted from the phase I study. No responses were seen in either disease.

摘要

已对19例晚期结肠癌患者和15例晚期恶性黑色素瘤患者进行了静脉输注，以每6小时8.6克/平方米的剂量给予黄酮醋酸（FAA）。药物相关毒性一般较轻，与I期研究预测的情况相符。两种疾病均未见缓解。

相似文献

1
Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.黄酮醋酸在晚期恶性黑色素瘤和结直肠癌中的II期试验。
Br J Cancer. 1989 Jul;60(1):104-6. doi: 10.1038/bjc.1989.230.
2
Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma.对晚期乳腺癌、结肠癌、头颈癌和黑色素瘤患者进行的黄酮醋酸（NCS. 347512，LM975）II期试验。
Invest New Drugs. 1990;8 Suppl 1:S95-9. doi: 10.1007/BF00171993.
3
Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors.黄酮醋酸（NSC 347512，LM975）用于小儿恶性实体瘤患者的I期研究。
Am J Clin Oncol. 1991 Dec;14(6):483-6. doi: 10.1097/00000421-199112000-00005.
4
A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2.黄酮 -8 - 乙酸与白细胞介素 -2联合应用的I期临床试验。
J Natl Cancer Inst. 1995 Jan 18;87(2):134-6. doi: 10.1093/jnci/87.2.134.
5
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study.重组白细胞介素-2（rIL-2）联合黄酮醋酸（FAA）治疗晚期恶性黑色素瘤：一项II期研究。
Br J Cancer. 1990 Apr;61(4):618-21. doi: 10.1038/bjc.1990.137.
6
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies.晚期恶性黑色素瘤中黄酮醋酸（FAA）联合重组白细胞介素-2（rIL-2）的研究：I. 临床和血管研究
Br J Cancer. 1993 Jun;67(6):1342-5. doi: 10.1038/bjc.1993.248.
7
Clinical and pharmacokinetic phase I trial with the diethylaminoester of flavone acetic acid (LM985, NSC 293015).黄酮乙酸二乙氨基酯（LM985，NSC 293015）的临床及药代动力学I期试验。
Eur J Cancer Clin Oncol. 1987 Jun;23(6):837-42. doi: 10.1016/0277-5379(87)90288-4.
8
Phase II trial with Flavone Acetic Acid (NSC.347512, LM975) in patients with non-small cell lung cancer.黄酮醋酸（NSC.347512，LM975）用于非小细胞肺癌患者的II期试验。
Ann Oncol. 1992 Feb;3(2):169-70. doi: 10.1093/oxfordjournals.annonc.a058137.
9
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. IV: Pharmacokinetics and toxicity of flavone acetic acid and its metabolites.晚期恶性黑色素瘤中黄酮醋酸（FAA）联合重组白细胞介素-2（rIL-2）的研究。IV：黄酮醋酸及其代谢产物的药代动力学和毒性
Br J Cancer. 1993 Jun;67(6):1351-5. doi: 10.1038/bjc.1993.250.
10
Phase I and pharmacokinetic study of flavone acetic acid.黄酮醋酸的I期及药代动力学研究
Cancer Res. 1987 Dec 15;47(24 Pt 1):6776-81.

引用本文的文献

1
Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice.小鼠中参与黄酮 - 8 - 乙酸代谢的细胞色素P450的鉴定与诱导
Drug Metab Lett. 2011 Apr;5(2):73-84. doi: 10.2174/187231211795305221.
2
Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).非细菌来源的黄烷酮类药物 5'6-二甲基黄烷酮-4-乙酸（Vadimezan）激活核苷酸寡聚化结构域信号通路。
J Biol Chem. 2010 Apr 2;285(14):10553-62. doi: 10.1074/jbc.M109.065631. Epub 2010 Jan 29.
3
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.化疗药物DMXAA能有效且特异性地激活TBK1-IRF-3信号轴。
J Exp Med. 2007 Jul 9;204(7):1559-69. doi: 10.1084/jem.20061845. Epub 2007 Jun 11.
4
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.汤姆·康纳斯教授与英国癌症研究中心I/II期临床试验委员会新型癌症疗法的研发。
Br J Cancer. 2003 Aug 4;89(3):437-54. doi: 10.1038/sj.bjc.6601106.
5
A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors.一种新型的康普瑞汀A-4衍生物AC-7700，对晚期实体瘤和原位移植瘤显示出显著的抗肿瘤活性。
Jpn J Cancer Res. 1999 Sep;90(9):1016-25. doi: 10.1111/j.1349-7006.1999.tb00850.x.
6
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies.晚期恶性黑色素瘤中黄酮醋酸（FAA）联合重组白细胞介素-2（rIL-2）的研究：I. 临床和血管研究
Br J Cancer. 1993 Jun;67(6):1342-5. doi: 10.1038/bjc.1993.248.
7
Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.评估硝基咪唑RSU1069及其前药RB6145的生物还原有效性：特别参考体内评估方法。
Cancer Metastasis Rev. 1993 Jun;12(2):177-93. doi: 10.1007/BF00689809.
8
Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).可生物还原的芥子气：可扩散细胞毒素（HPDC）的低氧选择性前药范例。
Cancer Metastasis Rev. 1993 Jun;12(2):135-51. doi: 10.1007/BF00689806.
9
Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.每周给药两或三次且不进行碱化处理的黄酮乙酸的I期及药理学研究
Cancer Chemother Pharmacol. 1995;35(3):219-24. doi: 10.1007/BF00686551.
10
Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
Br J Cancer. 1995 Jun;71(6):1204-9. doi: 10.1038/bjc.1995.234.

本文引用的文献

1
Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors.黄酮乙酸的治疗作用与药代动力学关系：一种对实体瘤有活性的药物
Cancer Treat Rep. 1986 Dec;70(12):1415-21.
2
Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).LM985（黄酮乙酸酯）的I期及药代动力学研究。
Cancer Res. 1986 Jun;46(6):3142-6.
3
Phase I and pharmacokinetic study of flavone acetic acid.黄酮醋酸的I期及药代动力学研究
Cancer Res. 1987 Dec 15;47(24 Pt 1):6776-81.
4
Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours.黄酮乙酸（NSC 347512）可诱导小鼠结肠26和38肿瘤发生出血性坏死。
Eur J Cancer Clin Oncol. 1987 Aug;23(8):1209-11. doi: 10.1016/0277-5379(87)90157-x.
5
Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.黄酮乙酸（NSC - 347512）对小鼠实体瘤的活性。
Invest New Drugs. 1986;4(3):207-20. doi: 10.1007/BF00179586.
6
Flavone acetic acid (NSC 347512)-induced DNA damage in Glasgow osteogenic sarcoma in vivo.
Cancer Res. 1988 Mar 1;48(5):1279-85.
7
Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta.黄酮乙酸对自然杀伤细胞活性的免疫调节作用：通过诱导α/β干扰素实现。
J Natl Cancer Inst. 1988 Oct 5;80(15):1226-31. doi: 10.1093/jnci/80.15.1226.
8
Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy.通过体内核磁共振波谱监测黄酮乙酸（NSC 347512）对小鼠肿瘤生理学的调节作用。
Cancer Res. 1988 Sep 1;48(17):4749-55.
9
Immune thrombocytopenia caused by flavone-8-acetic acid.黄酮 - 8 - 乙酸引起的免疫性血小板减少症。
Lancet. 1988 Feb 20;1(8582):412. doi: 10.1016/s0140-6736(88)91201-9.